<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601171</url>
  </required_header>
  <id_info>
    <org_study_id>345/11</org_study_id>
    <nct_id>NCT01601171</nct_id>
  </id_info>
  <brief_title>The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)</brief_title>
  <official_title>The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the genetic basis of reproductive disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The World Health Organization estimates approximately 10% of couples experience some sort of
      infertility problem.

      In humans, puberty is the process through which we develop reproductive capacity. Disorders
      of puberty have provided insight into the biology of reproduction and genetic technologies
      have enabled us to deepen understanding in this field. The focus of this study is to better
      understand the genetic control of puberty and human reproduction.

      Increasing understanding of the molecular basis (genes) of inherited reproductive disorders
      may enable investigators to:

        -  improve diagnostic testing and treatments for these problems

        -  develop new diagnostic tests and therapies for patients

        -  enhance counseling for patients and families with reproductive disorders
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>rare sequence variant(s) in gene(s)</measure>
    <time_frame>1 year (ongoing if no variants are identified)</time_frame>
    <description>The investigators aim to discover genes associated with reproductive disorders by identifying rare sequence variants (mutations) in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>functionality of identified rare sequence variants (mutations)</measure>
    <time_frame>1 year (following variant identification)</time_frame>
    <description>The investigators will use a variety of scientific approaches to assess the functional impact of the identified rare sequence variants (mutations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mode of inheritance</measure>
    <time_frame>1 year (following variant identification)</time_frame>
    <description>The investigators will examine family pedigrees and study family members to determine the inheritance patterns (how the disorder is transmitted in the family)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genotype-phenotype correlation</measure>
    <time_frame>1 year (following variant identification)</time_frame>
    <description>The investigators will study the phenotypic spectrum (how the disorder presents clinically) in patients with identified rare sequence variants (mutations)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Kallmann Syndrome</condition>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <condition>Hypothalamic Amenorrhea</condition>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with reproductive disorders will be recruited for: specimen collection (DNA/serum/plasma), completion of medical questionnairre, smell testing, and review of medical records.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Family members</arm_group_label>
    <description>Family members of patients with reproductive disorders will be recruited for: specimen collection (DNA/serum/plasma), completion of medical questionnairre, and smell testing.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum/plasma, white blood cells, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be a convenience sample of those patients with reproductive
        disorders (and their family members) who are interested in participating in this genetic
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:(any of the following conditions)

          -  hypogonadotropic hypogonadism

          -  Kallmann syndrome

          -  adult-onset hypogonadotropic hypogonadism

          -  hypothalamic amenorrhea

          -  polycystic ovarian syndrome

          -  primary gonadal failure

          -  precocious puberty

          -  family members of the above groups

        Exclusion Criteria:

          -  acute illness/hospitalization

          -  pituitary tumors

          -  iron overload (hemochromatosis)

          -  infiltrative diseases (sarcoidosis)

          -  chronic alcohol abuse

          -  illicit drug use

          -  anabolic steroid abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Pitteloud, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hositalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle Paccou</last_name>
    <phone>+41 79 556 60 13</phone>
    <email>emmanuelle.paccou@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng Xu, MD</last_name>
    <phone>+41 079 556 85 15</phone>
    <email>cheng.xu@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Paccou</last_name>
      <phone>+41 79 556 60 13</phone>
      <email>emmanuelle.paccou@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cheng Xu, MD</last_name>
      <phone>+41 079 556 85 15</phone>
      <email>cheng.xu@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Nelly Pitteloud, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.chuv.ch/edm/edm_home/edm-recherche/edm-research-groups/edm-researchgroup-pitteloud.htm</url>
    <description>Web page for the Principal Investigator Nelly Pitteloud's research group</description>
  </link>
  <results_reference>
    <citation>Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, Beenken A, Clarke J, Pers TH, Dworzynski P, Keefe K, Niedziela M, Raivio T, Crowley WF Jr, Seminara SB, Quinton R, Hughes VA, Kumanov P, Young J, Yialamas MA, Hall JE, Van Vliet G, Chanoine JP, Rubenstein J, Mohammadi M, Tsai PS, Sidis Y, Lage K, Pitteloud N. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet. 2013 May 2;92(5):725-43. doi: 10.1016/j.ajhg.2013.04.008.</citation>
    <PMID>23643382</PMID>
  </results_reference>
  <results_reference>
    <citation>Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, Sykiotis GP, Beenken A, Liu Y, Tommiska J, Hu Y, Tiosano D, Gerard M, Leger J, Drouin-Garraud V, Lefebvre H, Polak M, Carel JC, Phan-Hug F, Hauschild M, Plummer L, Rey JP, Raivio T, Bouloux P, Sidis Y, Mohammadi M, de Roux N, Pitteloud N. Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. Genet Med. 2015 Aug;17(8):651-9. doi: 10.1038/gim.2014.166. Epub 2014 Nov 13.</citation>
    <PMID>25394172</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Nelly Pitteloud</investigator_full_name>
    <investigator_title>Professor of Medicine, Chief of Service</investigator_title>
  </responsible_party>
  <keyword>GnRH deficiency</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>anosmia</keyword>
  <keyword>infertility</keyword>
  <keyword>cleft lip</keyword>
  <keyword>cleft palate</keyword>
  <keyword>cryptorchidism</keyword>
  <keyword>microphallus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
    <mesh_term>Puberty, Precocious</mesh_term>
    <mesh_term>Kallmann Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

